FBR Capital Downgrades Synta Pharma. (SNTA) to Market Perform Amid GALAXY-2 Termination
Tweet Send to a Friend
FBR Capital downgraded Synta Pharma. (NASDAQ: SNTA) from Outperform to Market Perform and cuts its price target from $6 to ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
